Skip to main content
SpringerLink
Log in

Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies

  • Chapter
  • First Online:
Bone Marrow Biopsy Pathology

Part of the book series: Essentials of Diagnostic Pathology ((ESSENTPATH))

Abstract

The descriptive term “Leukämie/leukemia” was introduced by Rudolf Virchow who noticed the “white” color of blood samples obtained from patients presenting with high peripheral white blood cell counts and a reversed white and red blood cell balance [1]. The designation “acute leukemia” (AL) is actually applied to a heterogeneous group of immature clonal hematopoietic neoplasms occurring in all age groups. The large majority of AL is derived from either the myeloid or the lymphoid lineage, allowing a definite classification as acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL). The rare category “AL of ambiguous lineage” includes AL with no lineage-specific features and AL of mixed lymphoid/myeloid phenotype (MPAL) [2, 3].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Kampen KR. The discovery and early understanding of leukemia. Leuk Res. 2012;36(1):6–13. https://doi.org/10.1016/j.leukres.2011.09.028. Epub 2011 Oct 26.

    Article  PubMed  Google Scholar 

  2. Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, Bloomfield CD, Cazzola M, Vardiman JW. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–405. https://doi.org/10.1182/blood-2016-03-643544. Epub 2016 Apr 11. Review.

    Article  CAS  PubMed  Google Scholar 

  3. Kurzer JH, Weinberg OK. Acute Leukemias of Ambiguous Lineage: Clarification on Lineage Specificity. Surg Pathol Clin. 2019;12(3):687–97. https://doi.org/10.1016/j.path.2019.03.008. Review.

    PubMed  Google Scholar 

  4. Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease. Blood. 2017;129(15):2103–10. https://doi.org/10.1182/blood-2016-09-687889. Epub 2017 Feb 8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Niemeyer CM, Mecucci C. Practical considerations for diagnosis and management of patients and carriers. Semin Hematol. 2017;54(2):69–74. https://doi.org/10.1053/j.seminhematol.2017.04.002. Epub 2017 Apr 6.

    Article  PubMed  Google Scholar 

  6. Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien HF, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47. https://doi.org/10.1182/blood-2016-08-733196. Epub 2016 Nov 28. Review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Weinberg OK, Sohani AR, Bhargava P, Nardi V. Diagnostic work-up of acute myeloid leukemia. Am J Hematol. 2017;92(3):317–21. https://doi.org/10.1002/ajh.24648. Epub 2017 Feb 3. Review.

    Article  PubMed  Google Scholar 

  8. Arber DA, Borowitz MJ, Cessna M, Etzell J, Foucar K, Hasserjian RP, Rizzo JD, Theil K, Wang SA, Smith AT, Rumble RB, Thomas NE, Vardiman JW. Initial diagnostic workup of acute leukemia: guideline from the College of American Pathologists and the American Society of Hematology. Arch Pathol Lab Med. 2017; https://doi.org/10.5858/arpa.2016-0504-CP. [Epub ahead of print].

  9. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group. Ann Intern Med. 1985;103:626–9.

    Google Scholar 

  10. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51. https://doi.org/10.1182/blood-2009-03-209262. Epub 2009 Apr 8. Review.

    Article  CAS  PubMed  Google Scholar 

  11. Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Foucar K, Döhner H, Bloomfield CD. AML with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification. Revised 4 ed. Lyon: IARC Press; 2017. p. 130–49.

    Google Scholar 

  12. Arber DA, Brunning RD, Orazi A, Bain BJ, Porwit A, Le Beau MM, Greenberg PL. AML with myelodysplasia-related changes. In: Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification. Revised 4 ed. Lyon: IARC Press; 2017. p. 150–2.

    Google Scholar 

  13. Vardiman JW, Arber DA, Brunning RD, Larson RA, Matutes E, Baumann I, Kvasnicka HM. Therapy-related myeloid neoplasms. In: Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification. Revised 4 ed. Lyon: IARC Press; 2017. p. 153–5.

    Google Scholar 

  14. Arber DA, Brunning RD, Orazi A, Porwit A, Peterson LC, Thiele J, Le Beau MM, Hassedjian RP. Acute myeloid leukemia, NOS. In: Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification. Revised 4 IARC Press, Lyon 2017. pp 156–66.

    Google Scholar 

  15. Pileri SA, Orazi A, Falini P. Myeloid sarcoma. In Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J. WHO classification. Revised 4 pp 167–168, IARC Press, Lyon 2017.

    Google Scholar 

  16. Arber DA, Baumann I, Niemeyer CM, Brunning RD, Porwit A. Myeloid proliferations associated with Down syndrome. In: Swerdlow SH, Campo E, Haris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification. Revised 4 ed. Lyon: IARC Press; 2017. p. 169–71.

    Google Scholar 

  17. Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, Potter NE, Heuser M, Thol F, Bolli N, Gundem G, Van Loo P, Martincorena I, Ganly P, Mudie L, McLaren S, O’Meara S, Raine K, Jones DR, Teague JW, Butler AP, Greaves MF, Ganser A, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374(23):2209–21. https://doi.org/10.1056/NEJMoa1516192.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Grimwade D, Ivey A, Huntly BJ. Molecular landscape of acute myeloid leukemia in younger adults and its clinical relevance. Blood. 2016;127(1):29–41.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Taylor J, Xiao W, Abdel-Wahab O. Diagnosis and classification of hematologic malignancies on the basis of genetics. Blood. 2017;130(4):410–23. https://doi.org/10.1182/blood-2017-02-734541. Epub 2017 Jun 9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, Dombret H, Fenaux P, Grimwade D, Larson RA, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz MA, Sierra J, Tallman MS, Löwenberg B, Bloomfield CD, European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74. https://doi.org/10.1182/blood-2009-07-235358. Epub 2009 Oct 30.

    Article  CAS  PubMed  Google Scholar 

  21. Gerstung M, Papaemmanuil E, Martincorena I, Bullinger L, Gaidzik VI, Paschka P, Heuser M, Thol F, Bolli N, Ganly P, Ganser A, McDermott U, Döhner K, Schlenk RF, Döhner H, Campbell PJ. Precision oncology for acute myeloid leukemia using a knowledge bank approach. Nat Genet. 2017;49(3):332–40. https://doi.org/10.1038/ng.3756. Epub 2017 Jan 16.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Shysh AC, Nguyen LT, Guo M, Vaska M, Naugler C, Rashid-Kolvear F. The incidence of acute myeloid leukemia in Calgary, Alberta, Canada: a retrospective cohort study. BMC Public Health. 2017;18(1):94. https://doi.org/10.1186/s12889-017-4644-6.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Acute myeloid leukaemia (AML) incidence statistics. London: Cancer Research UK; 2016. http://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/leukaemia-aml/incidence.

  24. Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–107. Review.

    PubMed  Google Scholar 

  25. Zwaan CM, Kolb EA, Reinhardt D, Abrahamsson J, Adachi S, Aplenc R, De Bont ES, De Moerloose B, Dworzak M, Gibson BE, Hasle H, Leverger G, Locatelli F, Ragu C, Ribeiro RC, Rizzari C, Rubnitz JE, Smith OP, Sung L, Tomizawa D, van den Heuvel-Eibrink MM, Creutzig U, Kaspers GJ. Collaborative efforts driving progress in pediatric acute myeloid leukemia. J Clin Oncol. 2015;33(27):2949–62. https://doi.org/10.1200/JCO.2015.62.8289. Epub 2015 Aug 24. Review.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 2016;58(2):71–80. Review. https://doi.org/10.1111/ped.12865.

    Article  CAS  PubMed  Google Scholar 

  27. O’Donnell MR, Tallman MS, Abboud CN, Altman JK, Appelbaum FR, Arber DA, Bhatt V, Bixby D, Blum W, Coutre SE, De Lima M, Fathi AT, Fiorella M, Foran JM, Gore SD, Hall AC, Kropf P, Lancet J, Maness LJ, Marcucci G, Martin MG, Moore JO, Olin R, Peker D, Pollyea DA, Pratz K, Ravandi F, Shami PJ, Stone RM, Strickland SA, Wang ES, Wieduwilt M, Gregory K, Ogba N. Acute Myeloid Leukemia, Version 3.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(7):926–57. https://doi.org/10.6004/jnccn.2017.0116.

  28. Haferlach T, Winkemann M, Löffler H, Schoch R, Gassmann W, Fonatsch C, Schoch C, Poetsch M, Weber-Matthiesen K, Schlegelberger B. The abnormal eosinophils are part of the leukemic cell population in acute myelomonocytic leukemia with abnormal eosinophils (AML M4Eo) and carry the pericentric inversion 16: a combination of May-Grünwald-Giemsa staining and fluorescence in situ hybridization. Blood. 1996;87(6):2459–63.

    CAS  PubMed  Google Scholar 

  29. Haferlach T, Kohlmann A, Klein HU, Ruckert C, Dugas M, Williams PM, Kern W, Schnittger S, Bacher U, Löffler H, Haferlach C. AML with translocation t(8;16)(p11;p13) demonstrates unique cytomorphological, cytogenetic, molecular and prognostic features. Leukemia. 2009;23(5):934–43. https://doi.org/10.1038/leu.2008.388. Epub 2009 Feb 5.

    Article  CAS  PubMed  Google Scholar 

  30. Chen W, Konoplev S, Medeiros LJ, Koeppen H, Leventaki V, Vadhan-Raj S, Jones D, Kantarjian HM, Falini B, Bueso-Ramos CE. 18. Cuplike nuclei (prominent nuclear invaginations) in acute myeloid leukemia are highly associated with FLT3 internal tandem duplication and NPM1 mutation. Cancer. 2009;115(23):5481–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  31. Dimitrienko S, Vercauteren S. Auer rods in mature granulocytes of a patient with mixed lineage leukemia. Blood. 2012;119(19):4348.

    Google Scholar 

  32. Béné MC, Nebe T, Bettelheim P, Buldini B, Bumbea H, Kern W, Lacombe F, Lemez P, Marinov I, Matutes E, Maynadié M, Oelschlagel U, Orfao A, Schabath R, Solenthaler M, Tschurtschenthaler G, Vladareanu AM, Zini G, Faure GC, Porwit A. Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10. Leukemia. 2011;25(4):567–74. https://doi.org/10.1038/leu.2010.312. Epub 2011 Jan 21.

    Article  PubMed  Google Scholar 

  33. Buldini B, Rizzati F, Masetti R, Fagioli F, Menna G, Micalizzi C, Putti MC, Rizzari C, Santoro N, Zecca M, Disarò S, Rondelli R, Merli P, Pigazzi M, Pession A, Locatelli F, Basso G. Prognostic significance of flow-cytometry evaluation of minimal residual disease in children with acute myeloid leukaemia treated according to the AIEOP-AML 2002/01 study protocol. Br J Haematol. 2017;177(1):116–26. https://doi.org/10.1111/bjh.14523. Epub 2017 Feb 27.

    Article  PubMed  Google Scholar 

  34. Rowley JD. Identification of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet. 1973;16:109–12.

    CAS  PubMed  Google Scholar 

  35. Rowley JD. Chromosomal translocations: revisited yet again. Blood. 2008;112(6):2183–9. https://doi.org/10.1182/blood-2008-04-097931.

    Article  CAS  PubMed  Google Scholar 

  36. Grimwade D, Mrózek K. Diagnostic and prognostic value of cytogenetics in acute myeloid leukemia. Hematol Oncol Clin North Am. 2011;25(6):1135–61, vii. https://doi.org/10.1016/j.hoc.2011.09.018.

    Article  PubMed  Google Scholar 

  37. Döhner H. Implication of the molecular characterization of acute myeloid leukemia. Hematology Am Soc Hematol Educ Program. 2007:412–9.

    Google Scholar 

  38. Bullinger L, Döhner K, Döhner H. Genomics of acute myeloid leukemia diagnosis and pathways. J Clin Oncol. 2017;35(9):934–46. https://doi.org/10.1200/JCO.2016.71.2208. Epub 2017 Feb 13. Review.

    Article  CAS  PubMed  Google Scholar 

  39. Dillon R, Grimwade D. Just 1 test to diagnose AML?!! Blood. 2016;128(1):8–10. https://doi.org/10.1182/blood-2016-05-715060.

    Article  CAS  PubMed  Google Scholar 

  40. Herold T, Rothenberg-Thurley M, Grunwald VV, Janke H, Goerlich D, Sauerland MC, Konstandin NP, Dufour A, Schneider S, Neusser M, Ksienzyk B, Greif PA, Subklewe M, Faldum A, Bohlander SK, Braess J, Wörmann B, Krug U, Berdel WE, Hiddemann W, Spiekermann K, Metzeler KH. Validation and refinement of the revised 2017 European LeukemiaNet genetic risk stratification of acute myeloid leukemia. Leukemia. 2020 Mar 30. https://doi.org/10.1038/s41375-020-0806-0. Online ahead of print.

  41. Döhner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2016;8:733196.

    Google Scholar 

  42. Kayser S, Schlenk RF, Platzbecker U. Management of patients with acute promyelocytic leukemia. Leukemia. 2018;32(6):1277–94. Epub 2018 Apr 24.

    PubMed  Google Scholar 

  43. Baba SM, Pandith AA, Shah ZA, Baba RA. Pathogenetic implication of fusion genes in acute promyelocytic leukemia and their diagnostic utility. Clin Genet. 2019;95(1):41–52. https://doi.org/10.1111/cge.13372. Epub 2018 Jun 8. Review.

  44. Lo-Coco F, Cicconi L, Breccia M. Current standard treatment of adult acute promyelocytic leukaemia. Br J Haematol. 2016;172(6):841–54.

    PubMed  Google Scholar 

  45. Cicconi L, Fenaux P, Kantarjian H, Tallman M, Sanz MA, Lo-Coco F. Molecular remission as a therapeutic objective in acute promyelocytic leukemia. Leukemia. 2018; https://doi.org/10.1038/s41375-018-0219-5. Epub ahead of print] Review.

  46. Balduini CL. 100-Year-Old Haematologica Images: Acute Promyelocytic Leukemia. Haematologica. 2020 Jan 31;105(2):245. https://doi.org/10.3324/haematol.2020.247056. Print 2020.

  47. Wang HY, Rashidi HH. The new clinicopathologic and molecular findings in myeloid neoplasms with inv(3)(q21q26)/t(3;3)(q21;q26.2). Arch Pathol Lab Med. 2016;140(12):1404–10. Epub 2016 Sep 15.

    CAS  PubMed  Google Scholar 

  48. Sweet DL, Golomb HM, Rowley JD, Vardiman JM. Acute myelogenous leukemia and thrombocythemia associated with an abnormality of chromosome No. 3. Cancer Genet Cytogenet. 1979;1(1):33–7.

    Google Scholar 

  49. Hinai AA, Valk PJ. Review: aberrant EVI1 expression in acute myeloid leukaemia. Br J Haematol. 2016;172(6):870–8. https://doi.org/10.1111/bjh.13898. Epub 2016 Jan 5. Review.

    Article  CAS  PubMed  Google Scholar 

  50. Baldazzi C, Luatti S, Zuffa E, Papayannidis C, Ottaviani E, Marzocchi G, Ameli G, Bardi MA, Bonaldi L, Paolini R, Gurrieri C, Rigolin GM, Cuneo A, Martinelli G, Cavo M, Testoni N. Complex chromosomal rearrangements leading to MECOM overexpression are recurrent in myeloid malignancies with various 3q abnormalities. Genes Chromosomes Cancer. 2016;55(4):375–88. https://doi.org/10.1002/gcc.22341. Epub 2016 Jan 27.

    Article  CAS  PubMed  Google Scholar 

  51. Gröschel S, Sanders MA, Hoogenboezem R, et al. Mutational spectrum of myeloid malignancies with inv(3)/t(3;3) reveals a predominant involvement of RAS/RTK signaling pathways. Blood. 2015;125(1):133–9.

    PubMed  PubMed Central  Google Scholar 

  52. Lugthart S, Gröschel S, Beverloo HB, Kayser S, Valk PJ, van Zelderen-Bhola SL, Jan Ossenkoppele G, Vellenga E, van den Berg-de Ruiter E, Schanz U, Verhoef G, Vandenberghe P, Ferrant A, Köhne CH, Pfreundschuh M, Horst HA, Koller E, von Lilienfeld-Toal M, Bentz M, Ganser A, Schlegelberger B, Jotterand M, Krauter J, Pabst T, Theobald M, Schlenk RF, Delwel R, Döhner K, Löwenberg B, Döhner H. Clinical, molecular, and prognostic significance of WHO type inv(3)(q21q26.2)/t(3;3)(q21;q26.2) and various other 3q abnormalities in acute myeloid leukemia. J Clin Oncol. 2010;28(24):3890–8. https://doi.org/10.1200/JCO.2010.29.2771. Epub 2010 Jul 26.

    Article  PubMed  Google Scholar 

  53. Lin S, Mulloy JC, Goyama S. RUNX1-ETO Leukemia. Adv Exp Med Biol. 2017;962:151–73. https://doi.org/10.1007/978-981-10-3233-2_11.

    Article  CAS  PubMed  Google Scholar 

  54. Schnittger S, Tobias M, Kohl TM, Torsten Haferlach T, Wolfgang Kern W, Wolfgang Hiddemann W, Karsten Spiekermann K, Claudia Schoch C. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107:1791–9.

    CAS  PubMed  Google Scholar 

  55. Park SH, Chi HS, Cho YU, Jang S, Park CJ. Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients. Leuk Res. 2013;37(7):784–9.

    CAS  PubMed  Google Scholar 

  56. Micol JB, Duployez N, Boissel N, Petit A, Geffroy S, Nibourel O, Lacombe C, Lapillonne H, Etancelin P, Figeac M, Renneville A, Castaigne S, Leverger G, Ifrah N, Dombret H, Preudhomme C, Abdel-Wahab O, Jourdan E. Frequent ASXL2 mutations in acute myeloid leukemia patients with t(8;21)/RUNX1-RUNX1T1 chromosomal translocations. Blood. 2014;124(9):1445–9. https://doi.org/10.1182/blood-2014-04-571018. Epub 2014 Jun 27.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Jahn N, Agrawal M, Bullinger L, Weber D, Corbacioglu A, Gaidzik VI, Schmalbrock L, Thol F, Heuser M, Krauter J, Göhring G, Kündgen A, Fiedler W, Wattad M, Held G, Köhne CH, Horst HA, Lübbert M, Ganser A, Schlenk RF, Döhner H, Döhner K, Paschka P. Incidence and prognostic impact of ASXL2 mutations in adult acute myeloid leukemia patients with t(8;21)(q22;q22): a study of the German-Austrian AML Study Group. Leukemia. 2017;31(4):1012–5. https://doi.org/10.1038/leu.2017.18. Epub 2017 Jan 16.

    Article  CAS  PubMed  Google Scholar 

  58. Johnson RC, Ma L, Cherry AM, Arber DA, George TI. B-cell transcription factor expression and immunoglobulin gene rearrangement frequency in acute myeloid leukemia with t(8;21)(q22;q22). Am J Clin Pathol. 2013;140:355–62.

    PubMed  Google Scholar 

  59. Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.

    CAS  PubMed  Google Scholar 

  60. Delaunay J, Vey N, Leblanc T, Fenaux P, Rigal-Huguet F, Witz F, Lamy T, Auvrignon A, Blaise D, Pigneux A, Mugneret F, Bastard C, Dastugue N, Van den Akker J, Fière D, Reiffers J, Castaigne S, Leverger G, Harousseau JL, Dombret H. Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup. Blood. 2003;102(2):462–9.

    CAS  PubMed  Google Scholar 

  61. Salem A, Loghavi S, Tang G, Huh YO, Jabbour EJ, Kantarjian H, Wang W, Hu S, Luthra R, Medeiros LJ, Khoury JD. Myeloid neoplasms with concurrent BCR-ABL1 and CBFB rearrangements: A series of 10 cases of a clinically aggressive neoplasm. Am J Hematol. 2017;92(6):520–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  62. Rogers HJ, Hsi ED, Tang G, Wang SA, Bueso-Ramos CE, Lubin D, Morrissette JJ, Bagg A, Cherukuri DP, George TI, Peterson L, Liu YC, Mathew S, Orazi A, Hasserjian RP. Most myeloid neoplasms with deletion of chromosome 16q are distinct from acute myeloid leukemia with Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study. Am J Clin Pathol. 2017;147(4):411–9.

    CAS  PubMed  Google Scholar 

  63. Visconte V, Shetty S, Przychodzen B, Hirsch C, Bodo J, Maciejewski JP, Hsi ED, Rogers HJ. Clinicopathologic and molecular characterization of myeloid neoplasms with isolated (6;9)(p23;q34). Int J Lab Hematol. 2017;39(4):409–17. https://doi.org/10.1111/ijlh.12641.

    Article  CAS  PubMed  Google Scholar 

  64. Ommen HB, Touzart A, MacIntyre E, Kern W, Haferlach T, Haferlach C, Tobal K, Hokland P, Schnittger S. The kinetics of relapse in DEK-NUP214-positive acute myeloid leukemia patients. Eur J Haematol. 2015;95(5):436–41. https://doi.org/10.1111/ejh.12511. Epub 2015 Mar 13.

    Article  CAS  PubMed  Google Scholar 

  65. Sandahl JD, Coenen EA, Forestier E, Harbott J, Johansson B, Kerndrup G, Adachi S, Auvrignon A, Beverloo HB, Cayuela JM, Chilton L, Fornerod M, de Haas V, Harrison CJ, Inaba H, Kaspers GJ, Liang DC, Locatelli F, Masetti R, Perot C, Raimondi SC, Reinhardt K, Tomizawa D, von Neuhoff N, Zecca M, Zwaan CM, van den Heuvel-Eibrink MM, Hasle H. t(6;9)(p22;q34)/DEK-NUP214-rearranged pediatric myeloid leukemia: an international study of 62 patients. Haematologica. 2014;99(5):865–72. https://doi.org/10.3324/haematol.2013.098517. Epub 2014 Jan 17.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Foucar K, Anastasi J. Acute myeloid leukemia with recurrent cytogenetic abnormalities. Am J Clin Pathol. 2015;144(1):6–18.

    CAS  PubMed  Google Scholar 

  67. Tarlock K, Alonzo TA, Moraleda PP, Gerbing RB, Raimondi SC, Hirsch BA, Ravindranath Y, Lange B, Woods WG, Gamis AS, Meshinchi S. Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is associated with poor outcome in childhood AML regardless of FLT3-ITD status: a report from the Children’s Oncology Group. Br J Haematol. 2014;166(2):254–9. https://doi.org/10.1111/bjh.12852. Epub 2014 Mar 25.

    Article  PubMed  PubMed Central  Google Scholar 

  68. Heuser M. Therapy-related myeloid neoplasms: does knowing the origin help to guide treatment? Hematology Am Soc Hematol Educ Program. 2016;2016(1):24–32.

    PubMed  PubMed Central  Google Scholar 

  69. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25(8):1239–48.

    CAS  PubMed  Google Scholar 

  70. Bolouri H, Farrar JE, Triche T Jr, Ries RE, Lim EL, Alonzo TA, Ma Y, Moore R, Mungall AJ, Marra MA, Zhang J, Ma X, Liu Y, Liu Y, Auvil JMG, Davidsen TM, Gesuwan P, Hermida LC, Salhia B, Capone S, Ramsingh G, Zwaan CM, Noort S, Piccolo SR, Kolb EA, Gamis AS, Smith MA, Gerhard DS, Meshinchi S. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structural alterations and age-specific mutational interactions. Nat Med. 2018;24(1):103–12. https://doi.org/10.1038/nm.4439.

    Article  CAS  PubMed  Google Scholar 

  71. Meyer C, Burmeister T, Gröger D, Tsaur D, Fechina L, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–84. https://doi.org/10.1038/leu.2017.213.

    Article  CAS  PubMed  Google Scholar 

  72. Gröschel S, Schlenk RF, Engelmann J, Rockova V, Teleanu V, Kühn MW, et al. Deregulated expression of EVI1 defines a poor prognostic subset of MLL-rearranged acute myeloid leukemias: a study of the German-Austrian Acute Myeloid Leukemia Study Group and the Dutch-Belgian-Swiss HOVON/SAKK Cooperative Group. J Clin Oncol. 2013;31(1):95–103.

    PubMed  Google Scholar 

  73. Kühn MW, Bullinger L, Gröschel S, Krönke J, Edelmann J, Rücker FG, Eiwen K, Paschka P, Gaidzik VI, Holzmann K, Schlenk RF, Döhner H, Döhner K. Genome-wide genotyping of acute myeloid leukemia with translocation t(9;11)(p22;q23) reveals novel recurrent genomic alterations. Haematologica. 2014;99(8):e133–5.

    PubMed  PubMed Central  Google Scholar 

  74. Gruber TA, Downing JR. The biology of pediatric acute megakaryoblastic leukemia. Blood. 2015;126(8):943–9. https://doi.org/10.1182/blood-2015-05-567859.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  75. Teyssier AC, Lapillonne H, Pasquet M, Ballerini P, Baruchel A, Ducassou S, Fenneteau O, Petit A, Cuccuini W, Ragu C, Preudhomme C, Mercher T, Sirvent N, Leverger G. Acute megakaryoblastic leukemia (excluding Down syndrome) remains an acute myeloid subgroup with inferior outcome in the French ELAM02 trial. Pediatr Hematol Oncol. 2017;34(8):425–7. https://doi.org/10.1080/08880018.2017.1414905.

    Article  PubMed  Google Scholar 

  76. Klairmont MM, Hoskoppal D, Yadak N, Choi JK. The comparative sensitivity of immunohistochemical markers of megakaryocytic differentiation in acute megakaryoblastic leukemia. Am J Clin Pathol. 2018; https://doi.org/10.1093/ajcp/aqy074. [Epub ahead of print].

  77. Carroll A, Civin C, Schneider N, et al. The t(1;22) (p13;q13) is nonrandom and restricted to infants with acute megakaryoblastic leukemia: a Pediatric Oncology Group Study. Blood. 1991;78(3):748–52.

    CAS  PubMed  Google Scholar 

  78. Alford KA, Reinhardt K, Garnett C, et al.; International Myeloid Leukemia-Down Syndrome Study Group Analysis of GATA1 mutations in Down syndrome transient myeloproliferative disorder and myeloid leukemia. Blood. 2011;118(8):2222-2238.

    Google Scholar 

  79. Bhatt VR, Akhtari M, Bociek RG, Sanmann JN, Yuan J, Dave BJ, Sanger WG, Kessinger A, Armitage JO. Allogeneic stem cell transplantation for Philadelphia chromosome-positive acute myeloid leukemia. J Natl Compr Canc Netw. 2014;12(7):963–8.

    CAS  PubMed  Google Scholar 

  80. Lazarevic VL, Labopin M, Depei W, Yakoub-Agha I, Huynh A, Ljungman P, Schaap N, Cornelissen JJ, Maillard N, Pioltelli P, Gedde-Dahl T, Lenhoff S, Houhou M, Esteve J, Mohty M, Nagler A. Relatively favorable outcome after allogeneic stem cell transplantation for BCR-ABL1-positive AML: a survey from the acute leukemia working party of the European Society for blood and marrow transplantation (EBMT). Am J Hematol. 2018;93(1):31–9. https://doi.org/10.1002/ajh.24928. Epub 2017.

    Article  CAS  PubMed  Google Scholar 

  81. Neuendorff NR, Burmeister T, Dörken B, Westermann J. BCR-ABL-positive acute myeloid leukemia: a new entity? Analysis of clinical and molecular features. Ann Hematol. 2016;95(8):1211–21. https://doi.org/10.1007/s00277-016-2721-z. Epub 2016 Jun 14. PMID: 27297971.

    Article  CAS  PubMed  Google Scholar 

  82. Neuendorff NR, Schwarz M, Hemmati P, Türkmen S, Bommer C, Burmeister T, Dörken B, le Coutre P, Arnold R, Westermann J. BCR-ABL1(+) acute myeloid leukemia: clonal selection of a BCR-ABL1(-) subclone as a cause of refractory disease with nilotinib treatment. Acta Haematol. 2015;133(2):237–41. https://doi.org/10.1159/000368176. Epub 2014 Nov 12.PMID: 25401297 Oct 31.

    Article  CAS  PubMed  Google Scholar 

  83. Falini B, Mecucci C, Tiacci E, Alcalay M, Rosati R, Pasqualucci L, La Starza R, Diverio D, Colombo E, Santucci A, Bigerna B, Pacini R, Pucciarini A, Liso A, Vignetti M, Fazi P, Meani N, Pettirossi V, Saglio G, Mandelli F, Lo-Coco F, Pelicci PG, Martelli MF, GIMEMA Acute Leukemia Working Party. N Engl J Med. 2005;352(3):254–66. Erratum in: N Engl J Med. 2005 Feb 7;352(7):740.

    CAS  Google Scholar 

  84. Falini B, Martelli MP, Bolli N, Sportoletti P, Liso A, Tiacci E, Haferlach T. Acute myeloid leukemia with mutated nucleophosmin (NPM1): is it a distinct entity? Blood. 2011;117(4):1109–20. Epub 2010 Oct 28.

    CAS  PubMed  Google Scholar 

  85. Heath EM, Chan SM, Minden MD, Murphy T, Shlush LI, Schimmer AD. Biological and clinical consequences of NPM1 mutations in AML. Leukemia. 2017;31(4):798–807. https://doi.org/10.1038/leu.2017.30. Epub 2017 Jan 23. Review.

    Article  CAS  Google Scholar 

  86. Falini B, Nicoletti I, Martelli MF, Mecucci C. Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood. 2007;109(3):874–85.

    CAS  PubMed  Google Scholar 

  87. Falini B, Macijewski K, Weiss T, Bacher U, Schnittger S, Kern W, Kohlmann A, Klein HU, Vignetti M, Piciocchi A, et al. Multilineage dysplasia has no impact on biologic, clinicopathologic, and prognostic features of aml with mutated nucleophosmin (NPM1). Blood. 2010;115:3776–86. https://doi.org/10.1182/blood-2009-08-240457. [PubMed] [Cross Ref].

    Article  CAS  Google Scholar 

  88. Schnittger S, Bacher U, Kern W, Alpermann T, Haferlach C, Haferlach T. Prognostic impact of FLT3-ITD load in NPM1 mutated acute myeloid leukemia. Leukemia. 2011;25:1297–304. https://doi.org/10.1038/leu.2011.97.

    Article  CAS  PubMed  Google Scholar 

  89. Bennett JM, Pryor J, Laughlin TS, Rothberg PG, Burack WR. Is the association of “cup-like” nuclei with mutation of the NPM1 gene in acute myeloid leukemia clinically useful? Am J Clin Pathol. 2010;134(4):648–52.

    PubMed  Google Scholar 

  90. Park BG, Chi HS, Jang S, Park CJ, Kim DY, Lee JH, Lee JH, Lee KH. Association of cup-like nuclei in blasts with FLT3 and NPM1 mutations in acute myeloid leukemia. Ann Hematol. 2013;92(4):451–7.

    CAS  PubMed  Google Scholar 

  91. Kunchala P, Kuravi S, Jensen R, McGuirk J, Balusu R. When the good go bad: mutant NPM1 in acute myeloid leukemia. Blood Rev. 2018;32(3):167–83. https://doi.org/10.1016/j.blre.2017.11.001. Epub 2017 Nov 4. Review.

    Article  CAS  PubMed  Google Scholar 

  92. Haferlach C, Mecucci C, Schnittger S, Kohlmann A, Mancini M, Cuneo A, Testoni N, Rege-Cambrin G, Santucci A, Vignetti M, et al. AML with mutated NPM1 carrying a normal or aberrant karyotype show overlapping biologic, pathologic, immunophenotypic, and prognostic features. Blood. 2009;114(14):3024–32. Epub 2009 May 8.

    CAS  Google Scholar 

  93. Medinger M, Passweg JR. Acute myeloid leukaemia genomics. Br J Haematol. 2017;179(4):530–42. https://doi.org/10.1111/bjh.14823. Epub 2017 Jun 27. Review.

    Article  CAS  PubMed  Google Scholar 

  94. Patel SS, Kuo FC, Gibson CJ, Steensma DP, Soiffer RJ, Alyea EP III, Chen YA, Fathi AT, Graubert TA, Brunner AM, Wadleigh M, Stone RM, DeAngelo DJ, Nardi V, Hasserjian RP, Weinberg OK. High NPM1-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AML. Blood. 2018;131(25):2816–25. https://doi.org/10.1182/blood-2018-01-828467. Epub 2018 May 3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Perry M, Bertoli S, Rocher C, Hayette S, Ducastelle S, Barraco F, Labussière-Wallet H, Salles G, Recher C, Thomas X, Paubelle E. FLT3-TKD mutations associated with NPM1 mutations define a favorable-risk group in patients with acute myeloid leukemia. Clin Lymphoma Myeloma Leuk. 2018;18:e545–50. pii: S2152-2650(18)30224-6.

    PubMed  Google Scholar 

  96. van de Kerkhof D, Scharnhorst V, Huysentruyt CJ, Brands-Nijenhuis AV, Ermens AA. Charcot-Leyden crystals in acute myeloid leukemia. Int J Lab Hematol. 2015;37(4):e100–2. https://doi.org/10.1111/ijlh.12336. Epub 2015 Mar 9.

    Article  PubMed  Google Scholar 

  97. Taylor G1, Ivey A, Milner B, Grimwade D, Culligan D. Acute myeloid leukaemia with mutated NPM1 presenting with extensive bone marrow necrosis and Charcot-Leyden crystals. Int J Hematol. 2013;98(3):267–8. https://doi.org/10.1007/s12185-013-1394-9. Epub 2013 Jul 25.

    Article  PubMed  Google Scholar 

  98. Wouters BJ, Löwenberg B, Erpelinck-Verschueren CA, van Putten WL, Valk PJ, Delwel R. Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome. Blood. 2009;113(13):3088–91.

    CAS  PubMed  PubMed Central  Google Scholar 

  99. Dufour A, Schneider F, Metzeler K, et al. Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome. J Clin Oncol. 2010;28(4):570–7.

    CAS  PubMed  Google Scholar 

  100. Mannelli F, Ponziani V, Bencini S, Bonetti MI, Benelli M, Cutini I, Gianfaldoni G, Scappini B, Pancani F, Piccini M, Rondelli T, Caporale R, Gelli AM, Peruzzi B, Chiarini M, Borlenghi E, Spinelli O, Giupponi D, Zanghì P, Bassan R, Rambaldi A, Rossi G, Bosi A. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica. 2017;102(3):529–40.

    CAS  PubMed  PubMed Central  Google Scholar 

  101. Greif PA, Dufour A, Konstandin NP, Ksienzyk B, Zellmeier E, Tizazu B, Sturm J, Benthaus T, Herold T, Yaghmaie M, Dörge P, Hopfner KP, Hauser A, Graf A, Krebs S, Blum H, Kakadia PM, Schneider S, Hoster E, Schneider F, Stanulla M, Braess J, Sauerland MC, Berdel WE, Büchner T, Woermann BJ, Hiddemann W, Spiekermann K, Bohlander SK. GATA2 zinc finger 1 mutations associated with biallelic CEBPA mutations define a unique genetic entity of acute myeloid leukemia. Blood. 2012;120(2):395–403.

    CAS  PubMed  Google Scholar 

  102. Gaidzik VI, Teleanu V, Papaemmanuil E, Weber D, Paschka P, Hahn J, Wallrabenstein T, Kolbinger B, Köhne CH, Horst HA, Brossart P, Held G, Kündgen A, Ringhoffer M, Götze K, Rummel M, Gerstung M, Campbell P, Kraus JM, Kestler HA, Thol F, Heuser M, Schlegelberger B, Ganser A, Bullinger L, Schlenk RF, Döhner K, Döhner H. UNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features. Leukemia. 2016;30(11):2282.

    CAS  PubMed  Google Scholar 

  103. You E, Cho YU, Jang S, Seo EJ, Lee JH, Lee JH, Lee KH, Koh KN, Im HJ, Seo JJ, Park YM, Lee JK, Park CJ. Frequency and clinicopathologic features of RUNX1 mutations in patients with acute myeloid leukemia not otherwise specified. Am J Clin Pathol. 2017;148(1):64–72.

    CAS  PubMed  Google Scholar 

  104. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, Corbacioglu A, Krauter J, Schlegelberger B, Ganser A, Späth D, Kündgen A, Schmidt-Wolf IG, Götze K, Nachbaur D, Pfreundschuh M, Horst HA, Döhner H, Döhner K. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. J Clin Oncol. 2011;29(10):1364–72.

    PubMed  Google Scholar 

  105. Behrens K, Triviai I, Schwieger M, Tekin N, Alawi M, Spohn M, Indenbirken D, Ziegler M, Müller U, Alexander WS, Stocking C. Runx1 downregulates stem cell and megakaryocytic transcription programs that support niche interactions. Blood. 2016;127(26):3369–81.

    CAS  PubMed  Google Scholar 

  106. Daneshbod Y, Kohan L, Taghadosi V, Weinberg OK, Arber DA. Prognostic Significance of Complex Karyotypes in Acute Myeloid Leukemia. Curr Treat Options Oncol. 2019;20(2):15. https://doi.org/10.1007/s11864-019-0612-y. PMID: 30741367 Review.

    Google Scholar 

  107. Seymour JF, Döhner H, Butrym A, Wierzbowska A, Selleslag D, Jang JH, Kumar R, Cavenagh J, Schuh AC, Candoni A, Récher C, Sandhu I, Del Castillo TB, Al-Ali HK, Falantes J, Stone RM, Minden MD, Weaver J, Songer S, Beach CL, Dombret H. Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens. BMC Cancer. 2017;17(1):852.

    PubMed  PubMed Central  Google Scholar 

  108. Weinberg O, Gibson CJ, Blonquist TM, Neuberg D, Pozdnyakova O, Kuo F, Ebert BL, Hasserjian RP. Association of mutations with morphological dysplasia in de novo acute myeloid leukemia without 2016 WHO Classification-defined cytogenetic abnormalities. Haematologica. 2018;103(4):626–63.

    CAS  PubMed  PubMed Central  Google Scholar 

  109. Weinberg OK, Pozdnyakova O, Campigotto F, et al. Reproducibility and prognostic significance of morphologic dysplasia in de novo acute myeloid leukemia. Mod Pathol. 2015;28(7):965–76.

    CAS  PubMed  Google Scholar 

  110. Vardiman J, Reichard K. Acute myeloid leukemia with myelodysplasia-related changes. Am J Clin Pathol. 2015;144(1):29–43.

    CAS  PubMed  Google Scholar 

  111. Porwit A, Vardiman JW. Acute myeloid leukemia with expanded erythropoiesis. Haematologica. 2011;96(9):1241–3.

    PubMed  PubMed Central  Google Scholar 

  112. Wang SA, Hasserjian RP. Acute erythroleukemias, acute megakaryoblastic leukemias, and reactive mimics. Am J Clin Pathol. 2015;144:44–60.

    CAS  PubMed  Google Scholar 

  113. Miesner M, Haferlach C, Bacher U, Weiss T, Macijewski K, Kohlmann A, Klein HU, Dugas M, Kern W, Schnittger S, et al. Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). Blood. 2010;116(15):2742–51. Epub 2010 Jun 25.

    CAS  PubMed  Google Scholar 

  114. Weinberg OK, Hasserjian RP, Li B, Pozdnyakova O. Assessment of myeloid and monocytic dysplasia by flow cytometry in de novo AML helps define an AML with myelodysplasia-related changes category. J Clin Pathol. 2017;70(2):109–15.

    PubMed  Google Scholar 

  115. Devillier R, Mansat-De Mas V, Gelsi-Boyer V, Demur C, Murati A, Corre J, Prebet T, Bertoli S, Brecqueville M, Arnoulet C, Recher C, Vey N, Mozziconacci MJ, Delabesse E, Birnbaum D. Role of ASXL1 and TP53 mutations in the molecular classification and prognosis of acute myeloid leukemias with myelodysplasia-related changes. Oncotarget. 2015;6(10):8388–96.

    PubMed  PubMed Central  Google Scholar 

  116. Claerhout H, Lierman E, Michaux L, Verhoef G, Boeckx N. A monocentric retrospective study of 138 therapy-related myeloid neoplasms. Ann Hematol. 2018; https://doi.org/10.1007/s00277-018-3462-y. [Epub ahead of print].

  117. Ganser A, Heuser M. Therapy-related myeloid neoplasms. Curr Opin Hematol. 2017;24(2):152–8.

    CAS  PubMed  Google Scholar 

  118. Cleven AH, Nardi V, Ok CY, Goswami M, Dal Cin P, Zheng Z, Iafrate AJ, Abdul Hamid MA, Wang SA, Hasserjian RP. High p53 protein expression in therapy-related myeloid neoplasms is associated with adverse karyotype and poor outcome. Mod Pathol. 2015;28(4):552–63.

    CAS  PubMed  Google Scholar 

  119. Ok CY, Patel KP, Garcia-Manero G, Routbort MJ, Fu B, Tang G, Goswami M, Singh R, Kanagal-Shamanna R, Pierce SA, et al. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases. Leuk Res. 2015;39(3):348–54.

    CAS  PubMed  Google Scholar 

  120. Pantic M, Pfeifer D, Kapp-Schwoerer S, Ihorst G, Becker H, Zeiser R, Duyster J, Schmitt-Graeff A. TP53 abnormalities and chromosomal aneuploidy in acute panmyelosis with myelofibrosis. Leukemia. 201933(12):2956–2962. https://doi.org/10.1038/s41375-019-0523-8. Epub 2019 Jul 26.

    Google Scholar 

  121. Bennett JM, Catovsky D, Daniel MT, et al. Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-America n-British Cooperative Group. Ann Intern Med. 1985;103:620–5.

    CAS  PubMed  Google Scholar 

  122. Canaani J, Beohou E, Labopin M, Socié G, Huynh A, Volin L, Cornelissen J, Milpied N, Gedde-Dahl T, Deconinck E, Fegueux N, Blaise D, Mohty M, Nagler A. Impact of FAB classification on predicting outcome in acute myeloid leukemia, not otherwise specified, patients undergoing allogeneic stem cell transplantation in CR1: an analysis of 1690 patients from the acute leukemia working party of EBMT. Am J Hematol. 2017;92(4):344–50.

    PubMed  Google Scholar 

  123. Rose D, Haferlach T, Schnittger S, Perglerová K, Kern W, Haferlach C. Subtype-specific patterns of molecular mutations in acute myeloid leukemia. Leukemia. 2017;31(1):11–7.

    CAS  PubMed  Google Scholar 

  124. Bennett JM, Catovsky D, Daniel MT, et al. Proposal for the recognition of minimally differentiated acute myeloid leukaemia (AML-MO). Br J Haematol. 1991;78:325–9.

    CAS  PubMed  Google Scholar 

  125. Arber DA. Revisiting erythroleukemia. Curr Opin Hematol. 2017;24(2):146–51.

    PubMed  Google Scholar 

  126. Wang SA, Patel KP, Pozdnyakova O, Peng J, Zuo Z, Dal Cin P, Steensma DP, Hasserjian RP. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts. Mod Pathol. 2016;29(10):1221–31.

    CAS  PubMed  Google Scholar 

  127. Calvo X, Arenillas L, Luño E, Senent L, Arnan M, Ramos F, Ardanaz MT, Pedro C, Tormo M, Montoro J, et al. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes. Mod Pathol. 2016;29(12):1541–51.

    CAS  PubMed  Google Scholar 

  128. Alkharabsheh O, Al-Kali A, Saadeh S, He R, Viswanatha D, Greipp P, Reichard K, Shah M, Gangat N, Patnaik M, Hogan W, Litzow M, Alkhateeb H, Nguyen PL. The clinical outcomes of reclassified erythroleukemia (erythroid/myeloid) as myelodysplastic syndrome (MDS) per 2017 WHO guideline compared to MDS. Am J Hematol. 2018; https://doi.org/10.1002/ajh.25239. [Epub ahead of print].

  129. Qiu S, Jiang E, Wei H, Lin D, Zhang G, Wei S, Zhou C, Liu K, Wang Y, Liu B, et al. An analysis of 97 previously diagnosed de novo adult acute erythroid leukemia patients following the 2016 revision to World Health Organization classification. BMC Cancer. 2017;17(1):534. Epub 2017 Aug 9.

    PubMed  PubMed Central  Google Scholar 

  130. Reinig EF, Greipp PT, Chiu A, Howard MT, Reichard KK. De novo pure erythroid leukemia: refining the clinicopathologic and cytogenetic characteristics of a rare entity. Mod Pathol. 2018;31(5):705–17.

    PubMed  Google Scholar 

  131. Valent P, Sotlar K, Blatt K, Hartmann K, Reiter A, Sadovnik I, Sperr WR, Bettelheim P, Akin C, Bauer K, George TI, Hadzijusufovic E, Wolf D, Gotlib J, Mahon FX, Metcalfe DD, Horny HP, Arock M. Proposed diagnostic criteria and classification of basophilic leukemias and related disorders. Leukemia. 2017;31(4):788–97.

    CAS  PubMed  PubMed Central  Google Scholar 

  132. Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, Piccaluga PP, Agostinelli C, Asioli S, Novero D, Bisceglia M, Ponzoni M, Gentile A, Rinaldi P, Franco V, Vincelli D, Pileri A Jr, Gasbarra R, Falini B, Zinzani PL, Baccarani M. Myeloid sarcoma: clinico-pathologic, phenotypic and cytogenetic analysis of 92 adult patients. Leukemia. 2007;21:340–50.

    CAS  PubMed  Google Scholar 

  133. Campidelli C, Agostinelli C, Stitson R, Pileri SA. Myeloid sarcoma: extramedullary manifestation of myeloid disorders. Am J Clin Pathol. 2009;132(3):426–37.

    PubMed  Google Scholar 

  134. Almond LM, Charalampakis M, Ford SJ, Gourevitch D, Desai A. Myeloid sarcoma: presentation, diagnosis, and treatment. Clin Lymphoma Myeloma Leuk. 2017;17:263–7.

    PubMed  Google Scholar 

  135. Falini B, Lenze D, Hasserjian R, Coupland S, Jaehne D, Soupir C, Liso A, Martelli MP, Bolli N, Bacci F, Pettirossi V, Santucci A, Martelli MF, Pileri S, Stein H. Cytoplasmic mutated nucleophosmin (NPM) defines the molecular status of a significant fraction of myeloid sarcomas. Leukemia. 2007;21(7):1566–70.

    CAS  PubMed  Google Scholar 

  136. Choi M, Jeon YK, Sun CH, Yun HS, Hong J, Shin DY, Kim I, Yoon SS, Koh Y. RTK-RAS pathway mutation is enriched in myeloid sarcoma. Blood Cancer J. 2018;8(5):43.

    PubMed  PubMed Central  Google Scholar 

  137. Peterson LC, Bloomfield CD, Niemeyer CM, Döhner H, Godley LA. Myeloid neoplasms with germline predisposition. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 122–8.

    Google Scholar 

  138. Vinh DC, Patel SY, Uzel G, Anderson VL, Freeman AF, Olivier KN, Spalding C, Hughes S, Pittaluga S, Raffeld M, Sorbara LR, Elloumi HZ, Kuhns DB, Turner ML, Cowen EW, Fink D, Long-Priel D, Hsu AP, Ding L, Paulson ML, Whitney AR, Sampaio EP, Frucht DM, DeLeo FR, Holland SM. Autosomal dominant and sporadic monocytopenia with susceptibility to mycobacteria, fungi, papillomaviruses, and myelodysplasia. Blood. 2010;115(8):1519–29.

    CAS  PubMed  PubMed Central  Google Scholar 

  139. Rojek K, Nickels E, Neistadt B, Marquez R, Wickrema A, Artz A, van Besien K, Larson RA, Lee MK, Segal JP, King MC, Walsh T, Shimamura A, Keel SB, Churpek JE, Godley LA. Identifying inherited and acquired genetic factors involved in poor stem cell mobilization and donor-derived malignancy. Biol Blood Marrow Transplant. 2016;22(11):2100–3.

    CAS  PubMed  PubMed Central  Google Scholar 

  140. Churpek JE. Familial myelodysplastic syndrome/acute myeloid leukemia. Best Pract Res Clin Haematol. https://doi.org/10.1016/j.beha.2017.10.002.

  141. Wlodarski MW, Niemeyer CM. Introduction: genetic syndromes predisposing to myeloid neoplasia. Semin Hematol. 2017;54(2):57–9.

    PubMed  Google Scholar 

  142. Wlodarski MW, Hirabayashi S, Pastor V, Starý J, Hasle H, Masetti R, Dworzak M, Schmugge M, van den Heuvel-Eibrink M, Ussowicz M, De Moerloose B, Catala A, Smith OP, Sedlacek P, Lankester AC, Zecca M, Bordon V, Matthes-Martin S, Abrahamsson J, Kühl JS, Sykora KW, Albert MH, Przychodzien B, Maciejewski JP, Schwarz S, Göhring G, Schlegelberger B, Cseh A, Noellke P, Yoshimi A, Locatelli F, Baumann I, Strahm B, Niemeyer CM, EWOG-MDS. Prevalence, clinical characteristics, and prognosis of GATA2-related myelodysplastic syndromes in children and adolescents. Blood. 2016;127(11):1387–97.

    CAS  PubMed  Google Scholar 

  143. McReynolds LJ, Calvo KR, Holland SM. Germline GATA2 mutation and bone marrow failure. Hematol Oncol Clin North Am. 2018;32(4):713–28.

    PubMed  PubMed Central  Google Scholar 

  144. Drazer MW, Kadri S, Sukhanova M, Patil SA, West AH, Feurstein S, Calderon DA, Jones MF, Weipert CM, Daugherty CK, Ceballos-López AA, Raca G, Lingen MW, Li Z, Segal JP, Churpek JE, Godley LA. Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Adv. 2018;2(2):146–50.

    CAS  PubMed  PubMed Central  Google Scholar 

  145. Dickinson RE, Griffin H, Bigley V, Reynard LN, Hussain R, Haniffa M, Lakey JH, Rahman T, Wang XN, McGovern N, Pagan S, Cookson S, McDonald D, Chua I, Wallis J, Cant A, Wright M, Keavney B, Chinnery PF, Loughlin J, Hambleton S, Santibanez-Koref M, Collin M. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood. 2011;118(10):2656–8.

    CAS  PubMed  PubMed Central  Google Scholar 

  146. Hsu AP, Johnson KD, Falcone EL, Sanalkumar R, Sanchez L, Hickstein DD, Cuellar-Rodriguez J, Lemieux JE, Zerbe CS, Bresnick EH, Holland SM. GATA2 haploinsufficiency caused by mutations in a conserved intronic element leads to MonoMAC syndrome. Blood. 2013;121(19):3830–7, S1–7.

    CAS  PubMed  PubMed Central  Google Scholar 

  147. Spinner MA, Sanchez LA, Hsu AP, Shaw PA, Zerbe CS, Calvo KR, Arthur DC, Gu W, Gould CM, Brewer CC, Cowen EW, Freeman AF, Olivier KN, Uzel G, Zelazny AM, Daub JR, Spalding CD, Claypool RJ, Giri NK, Alter BP, Mace EM, Orange JS, Cuellar-Rodriguez J, Hickstein DD, Holland SM. GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. Blood. 2014;123(6):809–21.

    CAS  PubMed  PubMed Central  Google Scholar 

  148. McReynolds LJ, Yang Y, Yuen Wong H, Tang J, Zhang Y, Mulé MP, Daub J, Palmer C, Foruraghi L, Liu Q, Zhu J, Wang W, West RR, Yohe ME, Hsu AP, Hickstein DD, Townsley DM, Holland SM, Calvo KR, Hourigan CS. MDS-associated mutations in germline GATA2 mutated patients with hematologic manifestations. Leuk Res. 2019;76:70–5.

    CAS  PubMed  Google Scholar 

  149. Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology Am Soc Hematol Educ Program. 2016;2016(1):598–604.

    PubMed  PubMed Central  Google Scholar 

  150. Satgé D, Seidel MG. The pattern of malignancies in Down syndrome and its potential context with the immune system. Front Immunol. 2018;(9):3058.

    Google Scholar 

  151. Hasle H, Clemmensen IH, Mikkelsen M. Risks of leukaemia and solid tumours in individuals with Down’s syndrome. Lancet. 2000;355:165–9.

    CAS  PubMed  Google Scholar 

  152. Bhatnagar N, Nizery L, Tunstall O, Vyas P, Roberts I. Transient abnormal myelopoiesis and AML in Down syndrome: an update. Curr Hematol Malig Rep. 2016;11(5):333–41.

    PubMed  PubMed Central  Google Scholar 

  153. Roberts I, Izraeli S. Haematopoietic development and leukaemia in Down syndrome. Br J Haematol. 2014;167(5):587–99.

    CAS  PubMed  Google Scholar 

  154. Watanabe K. Recent advances in understanding transient abnormal myelopoiesis in Down syndrome. Pediatr Int. 2018; https://doi.org/10.1111/ped.13776. [Epub ahead of print].

  155. Saida S. Evolution of myeloid leukemia in children with Down syndrome. Int J Hematol. 2016;103(4):365–72. https://doi.org/10.1007/s12185-016-1959-5. Epub 2016 Feb 24.

    Article  CAS  PubMed  Google Scholar 

  156. Facchetti F, Petrella T, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 174–7.

    Google Scholar 

  157. Facchetti F, Cigognetti M, Fisogni S, Rossi G, Lonardi S, Vermi W. Neoplasms derived from plasmacytoid dendritic cells. Mod Pathol. 2016;29(2):98–111.

    CAS  PubMed  Google Scholar 

  158. Suzuki Y, Kato S, Kohno K, Satou A, Eladl AE, Asano N, Kono M, Kato Y, Taniwaki M, Akiyama M, Nakamura S. Clinicopathological analysis of 46 cases with CD4+ and/or CD56+ immature haematolymphoid malignancy: reappraisal of blastic plasmacytoid dendritic cell and related neoplasms. Histopathology. 2017;71(6):972–84.

    PubMed  Google Scholar 

  159. Sullivan JM, Rizzieri DA. Treatment of blastic plasmacytoid dendritic cell neoplasm. Hematology Am Soc Hematol Educ Program. 2016;(1):16–23.

    Google Scholar 

  160. Khoury JD. Blastic plasmacytoid dendritic cell neoplasm. Curr Hematol Malig Rep. 2018;13(6):477–83.

    PubMed  Google Scholar 

  161. Sapienza MR, Abate F, Melle F, Orecchioni S, Fuligni F, Etebari M, Tabanelli V, Laginestra MA, Pileri A, Motta G, Rossi M, Agostinelli C, Sabattini E, Pimpinelli N, Truni M, Falini B, Cerroni L, Talarico G, Piccioni R, Amente S, Indio V, Tarantino G, Brundu F, Paulli M, Berti E, Facchetti F, Dellino GI, Bertolini F, Tripodo C, Rabadan R, Pileri SA. Blastic plasmacytoid dendritic cell neoplasm: genomics mark epigenetic dysregulation as a primary therapeutic target. Haematologica. 2018; https://doi.org/10.3324/haematol.2018.202093. pii: haematol.2018.202093. [Epub ahead of print].

  162. Tang Z, Li Y, Wang W, Yin CC, Tang G, Aung PP, Hu S, Lu X, Toruner GA, Medeiros LJ, Khoury JD. Genomic aberrations involving 12p/ETV6 are highly prevalent in blastic plasmacytoid dendritic cell neoplasms and might represent early clonal events. Leuk Res. 2018;73:86–94.

    CAS  PubMed  Google Scholar 

  163. Borowitz MJ, Béné MC, Harris NL, Porwit A, Matutes E, Arber DA. Acute leukemias of ambiguous lineage. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 180–7.

    Google Scholar 

  164. Heesch S, Neumann M, Schwartz S, Bartram I, Schlee C, Burmeister T, Hänel M, Ganser A, Heuser M, Wendtner CM, Berdel WE, Gökbuget N, Hoelzer D, Hofmann WK, Thiel E, Baldus CD. Acute leukemias of ambiguous lineage in adults: molecular and clinical characterization. Ann Hematol. 2013;92(6):747–58.

    CAS  PubMed  Google Scholar 

  165. Béné MC. Biphenotypic, bilineal, ambiguous or mixed lineage: strange leukemias! Haematologica. 2009;94(7):891–3.

    PubMed  PubMed Central  Google Scholar 

  166. Béné MC, Porwit A. Acute leukemias of ambiguous lineage. Semin Diagn Pathol. 2012;29(1):12–8. Review.

    PubMed  Google Scholar 

  167. Porwit A, Béné MC. Acute leukemias of ambiguous origin. Am J Clin Pathol. 2015;144(3):361–76.

    CAS  PubMed  Google Scholar 

  168. Lao ZT, Ding LW, An O, Hattori N, Sun QY, Tan KT, Mayakonda A, Chuan WG, Madan V, Lin DC, Yang H, Koeffler HP. Mutational and transcriptomic profiling of acute leukemia of ambiguous lineage reveals obscure but clinically important lineage bias. Haematologica. 2018; https://doi.org/10.3324/haematol.2018.202911. pii: haematol.2018.202911. [Epub ahead of print].

  169. Borowitz MJ, Chan JKC, Béné M-C, Arber DA. T-lymphoblastic leukemia/lymphoma. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Lyon: International Agency for Research on Cancer; 2017. p. 209–12.

    Google Scholar 

  170. Belver L, Ferrando A. The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer. 2016;16(8):494–507.

    CAS  PubMed  Google Scholar 

  171. Bene MC, Castoldi G, Knapp W, Ludwig WD, Matutes E, Orfao A, van’t Veer MB. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995;9(10):1783–6.

    CAS  PubMed  Google Scholar 

  172. Zhou Y, Fan X, Routbort M, Cameron Yin C, Singh R, Bueso-Ramos C, Thomas DA, Milton DR, Medeiros LJ, Lin P. Absence of terminal deoxynucleotidyl transferase expression identifies a subset of high-risk adult T-lymphoblastic leukemia/lymphoma. Mod Pathol. 2013;26(10):1338–45.

    CAS  PubMed  Google Scholar 

  173. Zheng W, Medeiros LJ, Young KH, Goswami M, Powers L, Kantarjian HH, Thomas DA, Cortes JE, Wang SA. CD30 expression in acute lymphoblastic leukemia as assessed by flow cytometry analysis. Leuk Lymphoma. 2014;55(3):624–7.

    CAS  PubMed  Google Scholar 

  174. Jain N, Lamb AV, O’Brien S, Ravandi F, Konopleva M, Jabbour E, Zuo Z, Jorgensen J, Lin P, Pierce S, Thomas D, Rytting M, Borthakur G, Kadia T, Cortes J, Kantarjian HM, Khoury JD. Early T-cell precursor acute lymphoblastic leukemia/lymphoma (ETP-ALL/LBL) in adolescents and adults: a high-risk subtype. Blood. 2016;127(15):1863–9.

    CAS  PubMed  PubMed Central  Google Scholar 

  175. Wang P, Peng X, Deng X, Gao L, Zhang X, Feng Y. Diagnostic challenges in T-lymphoblastic lymphoma, early T-cell precursor acute lymphoblastic leukemia or mixed phenotype acute leukemia. A case report. Medicine (Baltimore). 2018;97(41):e12743.

    Google Scholar 

  176. Wenzinger C, Williams E, Gru AA. Updates in the pathology of precursor lymphoid neoplasms in the revised fourth edition of the WHO classification of tumors of hematopoietic and lymphoid tissues. Curr Hematol Malig Rep. 2018;13(4):275–88.

    PubMed  Google Scholar 

  177. Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, Advani R, Ghielmini M, Salles GA, Zelenetz AD, Jaffe ES. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  178. Borowitz JM, Chan JKC, Downing JR, Le Beau MM, Arber DA. B-lymphoblastic leukemia/lymphoma, not otherwise specified. B-lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, editors. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. International Agency for Research on Cancer: Lyon; 2017. p. 200–9.

    Google Scholar 

  179. Pui CH, Roberts KG, Yang JJ, Mullighan CG. Philadelphia chromosome-like acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2017;17(8):464–70.

    PubMed  PubMed Central  Google Scholar 

  180. Tasian SK, Loh ML, Hunger SP. Philadelphia chromosome-like acute lymphoblastic leukemia. Blood. 2017;130(19):2064–72.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Pathology, Medical University Graz, Graz, Austria

    Christine Beham-Schmid

  2. Albert-Ludwigs-University of Freiburg, Freiburg, Germany

    Annette Schmitt-Graeff

Authors
  1. Christine Beham-Schmid
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Annette Schmitt-Graeff
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christine Beham-Schmid .

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer-Verlag GmbH Germany, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Beham-Schmid, C., Schmitt-Graeff, A. (2020). Acute Leukemia of Myeloid, Lymphoid, and Ambiguous Lineage and Related Malignancies. In: Bone Marrow Biopsy Pathology. Essentials of Diagnostic Pathology. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-60309-3_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-60309-3_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-60307-9

  • Online ISBN: 978-3-662-60309-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation